PMID- 38444735
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240307
IS  - 2405-5808 (Electronic)
IS  - 2405-5808 (Linking)
VI  - 38
DP  - 2024 Jul
TI  - Gemigliptin, a potent selective dipeptidyl peptidase 4 inhibitor, protects 
      endothelial progenitor cells by oxidative stress via caspase-3 dependent pathway.
PG  - 101673
LID - 10.1016/j.bbrep.2024.101673 [doi]
LID - 101673
AB  - Endothelial progenitor cells (EPCs) are exclusive players in vasculogenesis and 
      endothelial regeneration. EPCs are of two types and their differentiation is 
      mediated by different growth factors. A decrease in EPC number and function 
      causes cardiovascular abnormalities and reduced angiogenesis. Various studies has 
      documented a role of EPCs in diabetes. EPCs treatment with different drugs 
      improve insulin secretion but causes other abnormalities. In vivo and in vitro 
      studies have reported anti glycation effect of gemigliptin but no data is 
      available on in vitro effect of gemigliptin on EPC number and functional 
      credibility. The current study was aimed to find an in vitro effect of 
      gemigliptin on EPC number and function along with an effective treatment dose of 
      gemigliptin. EPCs were isolated, cultured and phenotypically characterized using 
      Dil- AcLDL and ulex-lectin fluorescence staining. EPCs were then treated with 
      different doses of Zemiglo and their viability analyzed with viability assay 
      using water-soluble tetrazolium salt (WST-1), by Annexin V and Propidium Iodide 
      (PI) staining, senescence-associated beta-galactosidase (SA-beta-gal) staining, 
      western blot and Flow cytometric analysis of apoptotic signals. The results 
      demonstrated that the isolated EPCs has typical endothelial phenotypes. And these 
      EPCs were of two types based on morphology i.e., early and late EPCs. Gemigliptin 
      dose dependently improved the EPCs morphology and increased EPCs viability, the 
      most effective dose being the 20 muM. Gemigliptin at 10 muM, 20 muM and 50 muM 
      significantly increased the BCL-2 levels and at 20 muM significantly decreased the 
      Caspase-3 levels in EPCs. In conclusion, gemigliptin dose dependently effects the 
      EPCs viability and morphology through Caspase-3 signaling. Our results are the 
      first report of gemigliptin effect on EPC viability and morphology.
CI  - (c) 2024 Published by Elsevier B.V.
FAU - Lee, Mijung
AU  - Lee M
AD  - Neurology, Center for Medical Innovation, Seoul National University Hospital, 
      Seoul, South Korea.
FAU - Tariq, Amna Rashid
AU  - Tariq AR
AD  - Neurology, Center for Medical Innovation, Seoul National University Hospital, 
      Seoul, South Korea.
FAU - Kim, Manho
AU  - Kim M
AD  - Neurology, Seoul National University Hospital, Neuroscience and Dementia Research 
      Institute, Seoul National University College of Medicine, Seoul, South Korea.
LA  - eng
PT  - Journal Article
DEP - 20240302
PL  - Netherlands
TA  - Biochem Biophys Rep
JT  - Biochemistry and biophysics reports
JID - 101660999
PMC - PMC10914559
OTO - NOTNLM
OT  - Caspase-3
OT  - EPC morphology
OT  - Endothelial progenitor cell
OT  - Zemiglo
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2024/03/06 06:43
MHDA- 2024/03/06 06:44
PMCR- 2024/03/02
CRDT- 2024/03/06 03:53
PHST- 2023/12/22 00:00 [received]
PHST- 2024/02/14 00:00 [revised]
PHST- 2024/02/20 00:00 [accepted]
PHST- 2024/03/06 06:44 [medline]
PHST- 2024/03/06 06:43 [pubmed]
PHST- 2024/03/06 03:53 [entrez]
PHST- 2024/03/02 00:00 [pmc-release]
AID - S2405-5808(24)00037-2 [pii]
AID - 101673 [pii]
AID - 10.1016/j.bbrep.2024.101673 [doi]
PST - epublish
SO  - Biochem Biophys Rep. 2024 Mar 2;38:101673. doi: 10.1016/j.bbrep.2024.101673. 
      eCollection 2024 Jul.